Metagenomi Therapeutics, Inc. Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year One Through Five
Metagenomi Therapeutics, Inc. (MGX) had Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year One Through Five of $0 as of 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Notes › Debt and Equity Securities › Available-for-Sale Securities, Debt Maturities › Debt Securities, Available-for-Sale, Maturity, Allocated and Single Maturity Date, Amortized Cost
us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost · last filed 2026-08-10
- 2026-06-30: Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year One Through Five $0.00.
- 2026-03-31: Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year One Through Five $5.03M.
- 2025-12-31: Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year One Through Five $6.04M.
- 2025-09-30: Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year One Through Five $2.00M.
| Period end | Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year One Through Five |
|---|---|
| 2026-06-30 | $0.00 10-Q · filed 2026-08-10 |
| 2026-03-31 | $5.03M 10-Q · filed 2026-05-11 |
| 2025-12-31 | $6.04M 10-Q · filed 2026-08-10 |
| 2025-09-30 | $2.00M 10-Q · filed 2025-11-12 |
| 2025-06-30 | $15.81M 10-Q · filed 2025-08-12 |
| 2025-03-31 | $40.73M 10-Q · filed 2025-05-13 |
| 2024-12-31 | $66.73M 10-K · filed 2026-03-05 |
| 2024-09-30 | $93.60M 10-Q · filed 2024-11-13 |
| 2024-06-30 | $78.41M 10-Q · filed 2024-08-14 |
| 2024-03-31 | $48.74M 10-Q · filed 2024-05-14 |
| 2023-12-31 | $853.00K 10-K · filed 2025-03-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Scilex Holding Co (SCLX) | United States | $0.042B | -0.14 |
| LeonaBio, Inc. (LONA) | United States | $0.047B | -0.61 |
| Instil Bio, Inc. (TIL) | United States | $0.048B | -1.73 |
| Tevogen Inc. (TVGN) | United States | $0.049B | |
| aTYR PHARMA INC (ATYR) | United States | $0.033B | -0.98 |
| Inmune Bio, Inc. (INMB) | United States | $0.056B | -2.48 |
| ImageneBio, Inc. (IMA) | United States | $0.056B | -1.31 |
| Quince Therapeutics, Inc. (QNCX) | United States | $0.031B | |
| CEL SCI CORP (CVM) | United States | $0.030B | -0.81 |
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |